Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial - Associated Press

Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial  Associated Press

LIQ861was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDA -- NDA submission targeted for late 2019 ...



Comments

Popular posts from this blog

4 Symptoms of Stress You Should Never Ignore - AARP

Dyspnea (Shortness of Breath): Causes, Symptoms & Treatment - my.clevelandclinic.org

Top pulmonology news from July: FDA updates, antibiotics in cystic fibrosis, treatment of COPD exacerbations - Healio